Personalis to team up with MapKure for cancer therapy clinical trials
Author : Pankaj Singh | Published Date : 2021-03-31
Personalis Inc., a US-based cancer genomics company has announced to have signed a joint venture agreement with MapKure, LLC, a newly created entity owned by SpringWorks and BeiGene, that focuses solely on genetic disease drivers.
The partnership is intended for a clinical trial assay (CTA) relying on Personalis NeXT Platform, to augment the progression of BGB-3245, an experimental next-gen B-RAF inhibitor for the treatment of advanced and refractory solid tumor.
MapKure will be teaming up with Personalis to use its NeXT Platform as a final test for patients registered in MapKure’s Phase 1A and 1B dose expansion and escalation clinical trial. Additionally, MapKure will be able to take advantage of the breadth of Personalis’ NeXT Platform, which facilitates broad tumor immunogenomic profiling and combines multiple biomarker assays into one.
This will enable multidimensional viewing of the tumor and its microenvironment from a single specimen, which can further help MapKure determine if other biomarkers are clinically associated with BGB-3245.
Chief Executive Officer of Personalis, John West was quoted saying that, new cancer combination therapies and immunotherapy promote the need for the development of advanced composite biomarkers that replicate the complex biology while driving resistance and response to cancer therapy.
The NeXT Platform delivers extensive genomic information from the transcriptome & exome while providing information that can aid the identification of new biomarkers for biotechnology specialists such as MapKure.
Once MapKure selects these biomarkers, the company plans to further them as companion diagnostics for regulatory approval and submission, cited the CEO, while adding that Personalis looks forward to its collaboration with MapKure so that it can accelerate the development of cancer therapy in the clinic by exacting results from Personalis NeXT Platform.
Personalis conducts one of the largest sequencing operations in the world and is currently the only sequencing provider to the VA MVP, while MapKure is a clinical-stage company formed in 2019 to develop precision medicines to manage life-threatening diseases such as cancer.
Source Link –
About Author
Pankaj Singh . .
Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
Related News
Bayers new CEO initiates management job cuts to accelerate decision-making
Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>
Smurfit Kappa in Merger Talks with WestRock worth $19 Billion
Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>
RBC plans job cuts to take on anticipated economic softening
The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>